10.08.2011 • News

Brenntag Q2 Profit up 74.4%

Chemical distributor Brenntag reported Wednesday a sharp increase in second-quarter profit, helped by increased sales, with all regions contributing to the positive development.

Second-quarter net profit was €67.6 million, up 74.7% from €38.7 million last year. Operating EBITDA increased considerably by 9.6% to €167.7 million, the German company said.

Sales grew by 11.2% to €2.17 billion from €1.95 billion last year. The growth was 15.9% at constant exchange rates.

The company's new CEO, Steven Holland, provided an update on acquisitions. "-- we successfully concluded the purchase of G.S. Robins in St. Louis, Missouri a leading distributor and a valuable addition to our North American business in terms of extending our reach and further consolidation within one of our core markets."

"We also announced the signing of a purchase agreement for Zhong Yung Chemical Ltd. in June 2011 which provides us with a significant platform within an increasingly sophisticated Chinese market. There we expect to see long term sustainable growth for Brenntag based on the requirements for further value added services," he added.

The group also noted that Standard & Poor's has upgraded the credit rating of the company in June 2011 from BB+ to BBB- within the investment grade and Moody's from Ba2 to Ba1.

Anticipating further significant growth, the company expects operating EBITDA to be between €650 million and €670 million for full-year 2011.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read